Drugs / TAS3731
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05691660 | Jan 2023 → May 2024 | — | Taiho Pharmaceutical Co., Ltd. | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TAS3731 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05691660 ↗ |
| Route | Oral | “Oral administration,1 day,QD” NCT05691660 ↗ |